Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implement
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 "Copay ... inflate sales of brand drugs among patients with ... according to a new report  from the ... of the Inspector General (OIG). Federal anti-kickback laws prohibit ... that are subsidized by the federal government. ...
(Date:9/19/2014)... Today, iHealth Lab Inc. announced it has secured ... its first institutional round of funding. The strategic investment ... accelerate growth and innovation, and invest in additional sales ... Ventures will join iHealth,s board of directors, bringing added ... "We are very pleased to have Xiaomi ...
(Date:9/19/2014)... LUBBOCK, Texas , Sept. 19, 2014 Kiromic, ... today the addition of Kent Hance , the former ... vice chairman. Hance retired as chancellor in July 2014, after ... pleased to announce that Kent Hance , the most ... joined the Kiromic team not only as an investor, but ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2
... Feb. 20, 2011 NxStage® Medical, Inc. ... innovative dialysis products, today announced the latest interim results ... in overall quality of life benefits, significant improvement in ... Legs Syndrome (RLS) symptoms experienced by patients after 12 ...
... One year to the day of its introduction, the ... to its official company launch.  "Starting a new company takes ... about the industry and our place in it and now ... healthcare." Dr. McCord is no stranger to healthcare. ...
Cached Medicine Technology:New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 2New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 3New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 4
(Date:9/21/2014)... York (PRWEB) September 21, 2014 ... their Risk Management Portal designed for Diocesan risks. ... the intent to support effective risk management and ... to go live coinciding with Waldorf’s exhibition at ... 2014. , These applications were developed in collaboration ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... the past decade, as it has become saturated ... beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and ... also been facing increasing generic competition. However, the ... once-daily ICS and ICS/LABA therapies delivered by the ...
(Date:9/21/2014)... "I want to help people who are having ... money for chiropractors," said an inventor from St. Amat, ... for myself." , The Stretch is a device that ... and align the spine properly. It improves flexibility and ... nerves. Compact and easy to use, it's ideal for ...
(Date:9/21/2014)... 2014 (HealthDay News) -- Young women starting college understand ... foods they should eat. But they aren,t confident they ... to a new study. The study involved ... Illinois,s Peer Education Exercising and Eating Right program. The ... choose to eat if they were very busy with ...
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
Breaking Medicine News(10 mins):Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... WellPoint, Inc. (NYSE: WLP ) announced ... New York Attorney General regarding the manner in which ... terms of the Agreement with the Attorney General, WellPoint ... database, which it uses in determining out-of-network reimbursement for ...
... RI Researchers at Rhode Island Hospital have completed ... control measures during a possible flu pandemic. Their study ... from individuals showing no symptoms (asymptomatic) or from individuals ... The researchers call on the scientific community to ...
... LOUISVILLE, Ky., Feb. 18 Almost Family, Inc. (Nasdaq: ... nursing services, announced today that it will be added to ... on Friday, February 20, 2009.William Yarmuth, President and CEO of ... included in the S&P SmallCap 600 Index, as it adds ...
... Taking Control of Your Diabetes,(TCOYD) announced findings ... firm Yankelovich that found that more than one ... that excess weight has a positive effect on,the ... often contributes,to the development of diabetes, complicates proper ...
... love their meat. Whether it,s rib eyes, pork chops or ... this country that more than 85 billion pounds of meat ... About a quarter of U.S. beef and pork is exported ... now the world,s largest consumer of meat, in Mexico, meat ...
... Spanish . , A team of specialists ... of genetic variants that have greater resistance to a specific ... some child patients affected by osteosarcoma. The team investigated the ... therapeutic treatment in the future. , In concrete, the research ...
Cached Medicine News:Health News:WellPoint Joins New York Attorney General in Creation of New Independent Database for Out-of-Network Reimbursement 2Health News:Study calls for increased research in flu transmission to prepare for pandemic flu outbreak 2Health News:Almost Family to be Added to the S&P SmallCap 600 Index 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 3Health News:American Veterinary Medical Association: Weaving a Web for Food Safety 2Health News:Research increases possibilities of personalizing treatment of infant osteosarcoma 2Health News:Research increases possibilities of personalizing treatment of infant osteosarcoma 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: